[From AI to polygenic risk scores: which innovations will shape the future of psychiatry?]

In recent years, developments have been made in various research domains, from treatments with (es)ketamine to large-scale genome-wide association studies (GWAS).

To map some of the most promising scientific developments, that may have an impact on clinical practice in psychiatry or are already doing so.

We summarized recent developments in the field of epidemiology, artificial intelligence (AI) and genetics, supported by and illustrated with recent relevant scientific literature.

Triangulation of data and innovative trial designs, such as n=1 trials and platform trials, carry the potential to contribute to more reliable results and developments in precision psychiatry. AI has various possibilities for daily practice: from searching for evidence to applying therapeutic interventions via chatbots. GWAS enable individual genetic risk profile generation with ever-growing precision.

Multifaceted developments in psychiatric research are projected to render clinical psychiatry more efficient and treatment options more personalized. Bolstering (international) collaborations and co-creating with experts by experience are indispensable elements in determining the scientific course in the field for the years ahead.